Inglewood, Calif., May 12th, 2022– ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), today announced an agreement with Invicro LLC, a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to supply clinical doses of ImaginAb’s investigational CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) for use in clinical trials as part of Invicro’s global core lab imaging service. The agreement also allows Invicro to produce zirconium Zr 89 crefmirlimab for its preclinical offerings.

This offering is a response to the growth seen in I-O therapies and demand from pharmaceutical and biotech companies for advanced, non-invasive, whole-body imaging biomarkers. ImaginAb’s investigational CD8 ImmunoPET agent provides a number of potential benefits that may help inform early decision making through Phase I-IV I-O clinical trials.

(more…)

NEEDHAM, Mass., May 5, 2022 — Invicro LLC, a part of REALM IDx, Inc., today announced the relocation of its global headquarters and expansion of its U.S. laboratories for radiology and pathology imaging services to Needham, Mass., to provide more resources to support pharmaceutical and biotechnology companies and their development of life-changing drugs.

Imaging technologies, such as MRI, CT and PET are a critical and growing part of patient care, including the diagnosis, staging and tracking of disease and treatment. In the development of new medicines, imaging enables a personalized assessment of disease burden and drug response. Invicro’s imaging services and expanded facilities will provide more resources to pharmaceutical and biotechnology companies, offering next-generation biomarkers backed by world-class capabilities that support new drug discoveries for patient care that span from discovery research to global clinical trials.

(more…)

(BOSTON, MA) September 28, 2021 – Invicro LLC, a REALM IDx, Inc company, announces a collaboration with the National Institutes of Health’s new intramural research effort, the Center for Alzheimer’s and Related Dementias (CARD), through a data science contract with Data Tecnica International LLC (DTi), to offer a curated collection of harmonized brain imaging and genomics data that will help identify dementia and other neurodegenerative disorder risk factors to better stratify subjects and their disease progression.

“We are excited to collaborate with CARD on this significant effort,” stated Dr. Jacob Hesterman, Founding Partner and Chief Technology Officer for Invicro. “This collaboration provides an outstanding opportunity to make the highest quality image analysis available to the broader scientific community and contribute to the mission of Open Science. Together, we form the multi-disciplinary team needed to deliver on the promise of rich, curated multi-omic data offered by large, complex data sets.”

(more…)

Aliso Viejo, CA., May 4, 2021 — Konica Minolta Precision Medicine, Inc. (KMPM) announced today changes to its executive leadership team effective immediately. The changes reflect a thoughtful and strategic approach to the next phase of growth and expansion for the global precision diagnostics organization.

Aaron Elliott, current CEO of Ambry Genetics, has been named Chief Executive Officer of KMPM. In his new role, Dr. Elliott will be responsible for driving execution across all KMPM business units, which include Ambry Genetics, Invicro, and KMPM-Japan. During his 13-year tenure at Ambry, Dr. Elliott also served as Chief Operating Officer and Chief Scientific Officer, and saw the company through many trailblazing milestones including numerous novel first to market diagnostic tests, the landmark BRCA gene patent case which opened up genetic testing in the United States and the acquisition by Konica Minolta.

(more…)

Tokyo (March 10, 2021) – Konica Minolta Precision Medicine, Inc. (KMPM), a Konica Minolta Group company, announced today a five-year collaboration with Amazon Web Services, Inc. (AWS). As the Preferred Cloud Provider for KMPM, AWS will support the build-out of the company’s LATTICE^TM initiative globally. LATTICE^TM is a groundbreaking integrated diagnostic data platform that combines genomics, pathology, and radiology data along with other critical information to uncover new, clinically relevant biomarkers and create the next generation of diagnostic tests. As part of this collaboration, Amazon has made a financial investment in KMPM.

(more…)

BOSTON, MA, 01 February 2021 – Invicro LLC, a Konica Minolta company announces that the paper, Tau^IQ – A canonical image-based algorithm to quantify tau PET scans, will be published in The Journal of Nuclear Medicine (JNM). In conjunction with this publication, Invicro has launched 21 CFR Part 11 compliant Tau^IQ services in its Core Lab as part of its expanded IQ-Analytics Platform, which includes Amyloid^IQ and DaT^IQ.

(more…)

BOSTON, MA March 9, 2020, Invicro LLC, a Konica Minolta Company announced it has entered into a strategic research partnership with industry leading pathologist, Dr. David Rimm, MD, PhD, at The Yale University School of Medicine to advance the development of Quanticell, Konica Minolta’s propriety tissue biomarker detection technology.

(more…)

NEW PROVIDENCE, N.J. and BOSTON, MA, November 18, 2019 — Today, Evolution Research Group (ERG) and Invicro LLC, a Konica Minolta Company announced a strategic partnership to offer biotech and pharma sponsors early to late phase clinical research trials, advanced data analysis and project management services.

(more…)